AAOpt 2023: Update from BioTissue

Roger Kennedy, Director of Marketing of BioTissue, shares an overview on a poster on cryopreserved amniotic membrane and the effectiveness in moderate to severe dry eye disease over a 3 month timeframe, presented during the 2023 American Academy of Optometry meeting in New Orleans.

Editor's note: This transcript has been edited for clarity.

Roger Kennedy:

Hi, my name is Roger Kennedy. I'm the Director of Marketing for BioTissue. Today I want to talk to you about the poster that's going to be presented tomorrow at Academy of Optometry. It's virtually a poster on cryopreserved amniotic membrane and the effectiveness in moderate to severe dry [eye] disease over a 3 month timeframe.

The highlights of the story, or of the poster rather, is basically you have cryopreserved amniotic membrane being shown to reduce the signs and symptoms of moderate to severe dry [eye] disease. This was defined as either [stage] 3 or [stage] 4 dry eye disease, and we saw a reduction in signs and symptoms.

Then, what's new about this? This is a paper that has been published quite a bit ago, but we re-looked at the paper and evaluated at what time does it take for cryopreserved amniotic membrane to be effective in reducing the signs and symptoms. We saw no statistical significance between day 2 and day 5, which opens our eyes as far as the ability to have onset action of effectiveness.

Traditionally, we've been recommending anywhere from 3 to 5 days. Now, we are starting to have some sort of evidence to show that in as little as 2 days you can be effective in treating dry disease.